AbbVie (ABBV) Income from Continuing Operations (2012 - 2026)
AbbVie (ABBV) reported Income from Continuing Operations of 697000000.0 for Q1 2026, down 45.93% year-over-year from 1289000000.0 in Q1 2025, and down 61.6% on a QoQ basis from 1815000000.0 in Q4 2025.
AbbVie (ABBV) has 15 years of Income from Continuing Operations data on file, last reported at 697000000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 45.93% year-over-year to 697000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3641000000.0 (down 13.37% YoY) and the FY2025 annual result came in at 4233000000.0, down 1.24% from the prior year.
- Income from Continuing Operations eased to 697000000.0 in Q1 2026 per ABBV's latest filing, from 1815000000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4493000000.0 in Q1 2022 and bottomed at 97000000.0 in Q1 2023.
- The 5-year median for Income from Continuing Operations is 1372000000.0 (2024), against an average of 1505647058.82.
- The widest annual swing landed in 2024, when Income from Continuing Operations sank 102.79%; it then soared 7991.3% in 2025.
- Tracing ABBV's Income from Continuing Operations over 5 years: stood at 2472000000.0 in 2022, then tumbled by 66.67% to 824000000.0 in 2023, then slumped by 102.79% to 23000000.0 in 2024, then soared by 7991.3% to 1815000000.0 in 2025, then sank by 61.6% to 697000000.0 in 2026.
- Per Business Quant, the three latest ABBV Income from Continuing Operations figures stand at 697000000.0 (Q1 2026), 1815000000.0 (Q4 2025), and 188000000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 697.00 Mn |
| Dec 31, 2025 | 1.82 Bn |
| Sep 30, 2025 | 188.00 Mn |
| Jun 30, 2025 | 941.00 Mn |
| Mar 31, 2025 | 1.29 Bn |
| Dec 31, 2024 | -23.00 Mn |
| Sep 30, 2024 | 1.56 Bn |
| Jun 30, 2024 | 1.37 Bn |
| Mar 31, 2024 | 1.37 Bn |
| Dec 31, 2023 | 824.00 Mn |
| Sep 30, 2023 | 1.78 Bn |
| Jun 30, 2023 | 2.03 Bn |
| Mar 31, 2023 | -97.00 Mn |
| Dec 31, 2022 | 2.47 Bn |
| Sep 30, 2022 | 3.95 Bn |
| Jun 30, 2022 | 928.00 Mn |
| Mar 31, 2022 | 4.49 Bn |
| Dec 31, 2021 | 4.05 Bn |
| Sep 30, 2021 | 3.18 Bn |
| Jun 30, 2021 | 769.00 Mn |
| Mar 31, 2021 | 3.56 Bn |
| Dec 31, 2020 | 38.00 Mn |
| Sep 30, 2020 | 2.31 Bn |
| Jun 30, 2020 | -739.00 Mn |
| Mar 31, 2020 | 3.01 Bn |
| Dec 31, 2019 | 2.80 Bn |
| Sep 30, 2019 | 1.88 Bn |
| Jun 30, 2019 | 741.00 Mn |
| Mar 31, 2019 | 2.46 Bn |
| Dec 31, 2018 | -1.83 Bn |
| Sep 30, 2018 | 2.75 Bn |
| Jun 30, 2018 | 1.98 Bn |
| Mar 31, 2018 | 2.78 Bn |
| Dec 31, 2017 | 52.00 Mn |
| Sep 30, 2017 | 1.63 Bn |
| Jun 30, 2017 | 1.92 Bn |
| Mar 31, 2017 | 1.71 Bn |
| Dec 31, 2016 | 1.39 Bn |
| Sep 30, 2016 | 1.60 Bn |
| Jun 30, 2016 | 1.61 Bn |
| Mar 31, 2016 | 1.35 Bn |
| Dec 31, 2015 | 1.52 Bn |
| Sep 30, 2015 | 1.24 Bn |
| Jun 30, 2015 | 1.37 Bn |
| Mar 31, 2015 | 1.02 Bn |
| Dec 31, 2014 | -810.00 Mn |
| Sep 30, 2014 | 506.00 Mn |
| Jun 30, 2014 | 1.10 Bn |
| Mar 31, 2014 | 980.00 Mn |
| Dec 31, 2013 | 1.75 Bn |
| Sep 30, 2013 | 964.00 Mn |
| Jun 30, 2013 | 1.07 Bn |
| Mar 31, 2013 | 968.00 Mn |
| Dec 31, 2012 | 1.64 Bn |
| Sep 30, 2012 | 1.59 Bn |
| Jun 30, 2012 | 1.27 Bn |
| Mar 31, 2012 | 883.00 Mn |